{"title":"癌症的经济代价：揭示经济毒性与症状负担之间的联系。","authors":"Marco Filetti, Pasquale Lombardi, Gabriella Gentile, Paolo Toccaceli, Guglielmo Fumi, Denise Vacca, Emilia Colpani, Giulio Ravoni, Federica Mazzuca, Gennaro Daniele, Giampiero Porzio, Eduardo Bruera, Raffaele Giusti","doi":"10.1093/oncolo/oyaf131","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>This prospective observational study investigated the relationship between financial toxicity, symptom burden, disease characteristics and out-of-pocket (OOP) medication use in patients with cancer across 5 Italian institutions.</p><p><strong>Methods: </strong>A cross-sectional survey assessed financial toxicity, symptom burden and OOP costs sustained by patients with cancer using validated questionnaires (COST, PERSONS). Associations between financial toxicity (COST score), symptom burden (PERSONS score) and clinical variables were explored.</p><p><strong>Results: </strong>Among 211 respondents, mean COST score was 23 (SD 9.1) and 128 (60%) scored < 26, indicating financial toxicity. Symptom burden measured by the PERSONS score was associated with a higher OOP medications use (r = 0.449, P < .001) and inversely related to financial toxicity (r = -0.431; P < .001). In our study population, median number of OOP drug was 2 (IQR 1-2), most commonly analgesics and laxatives. There was a significantly worse COST score among patients using OOP analgesic: 19.8 (SD 9.5) vs 25.6 (SD 7.9), P < .001 and laxatives: 19.2 (SD 8.2) vs 24.4 [(SD 9.1), P < .00]. Overall, OOP drugs were linked to higher symptom burden (P < .001) and financial toxicity (P < .001).</p><p><strong>Conclusions: </strong>The severity of symptoms and their management with OOP medications was significantly associated with patients' financial toxicity. These findings highlight the importance of integrating financial toxicity assessment into routine cancer care to optimize patient outcomes and well-being.</p>","PeriodicalId":54686,"journal":{"name":"Oncologist","volume":"30 6","pages":""},"PeriodicalIF":4.8000,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12199244/pdf/","citationCount":"0","resultStr":"{\"title\":\"The financial toll of cancer: uncovering the links between financial toxicity and symptom burden.\",\"authors\":\"Marco Filetti, Pasquale Lombardi, Gabriella Gentile, Paolo Toccaceli, Guglielmo Fumi, Denise Vacca, Emilia Colpani, Giulio Ravoni, Federica Mazzuca, Gennaro Daniele, Giampiero Porzio, Eduardo Bruera, Raffaele Giusti\",\"doi\":\"10.1093/oncolo/oyaf131\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>This prospective observational study investigated the relationship between financial toxicity, symptom burden, disease characteristics and out-of-pocket (OOP) medication use in patients with cancer across 5 Italian institutions.</p><p><strong>Methods: </strong>A cross-sectional survey assessed financial toxicity, symptom burden and OOP costs sustained by patients with cancer using validated questionnaires (COST, PERSONS). Associations between financial toxicity (COST score), symptom burden (PERSONS score) and clinical variables were explored.</p><p><strong>Results: </strong>Among 211 respondents, mean COST score was 23 (SD 9.1) and 128 (60%) scored < 26, indicating financial toxicity. Symptom burden measured by the PERSONS score was associated with a higher OOP medications use (r = 0.449, P < .001) and inversely related to financial toxicity (r = -0.431; P < .001). In our study population, median number of OOP drug was 2 (IQR 1-2), most commonly analgesics and laxatives. There was a significantly worse COST score among patients using OOP analgesic: 19.8 (SD 9.5) vs 25.6 (SD 7.9), P < .001 and laxatives: 19.2 (SD 8.2) vs 24.4 [(SD 9.1), P < .00]. Overall, OOP drugs were linked to higher symptom burden (P < .001) and financial toxicity (P < .001).</p><p><strong>Conclusions: </strong>The severity of symptoms and their management with OOP medications was significantly associated with patients' financial toxicity. These findings highlight the importance of integrating financial toxicity assessment into routine cancer care to optimize patient outcomes and well-being.</p>\",\"PeriodicalId\":54686,\"journal\":{\"name\":\"Oncologist\",\"volume\":\"30 6\",\"pages\":\"\"},\"PeriodicalIF\":4.8000,\"publicationDate\":\"2025-06-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12199244/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oncologist\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1093/oncolo/oyaf131\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncologist","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/oncolo/oyaf131","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
The financial toll of cancer: uncovering the links between financial toxicity and symptom burden.
Purpose: This prospective observational study investigated the relationship between financial toxicity, symptom burden, disease characteristics and out-of-pocket (OOP) medication use in patients with cancer across 5 Italian institutions.
Methods: A cross-sectional survey assessed financial toxicity, symptom burden and OOP costs sustained by patients with cancer using validated questionnaires (COST, PERSONS). Associations between financial toxicity (COST score), symptom burden (PERSONS score) and clinical variables were explored.
Results: Among 211 respondents, mean COST score was 23 (SD 9.1) and 128 (60%) scored < 26, indicating financial toxicity. Symptom burden measured by the PERSONS score was associated with a higher OOP medications use (r = 0.449, P < .001) and inversely related to financial toxicity (r = -0.431; P < .001). In our study population, median number of OOP drug was 2 (IQR 1-2), most commonly analgesics and laxatives. There was a significantly worse COST score among patients using OOP analgesic: 19.8 (SD 9.5) vs 25.6 (SD 7.9), P < .001 and laxatives: 19.2 (SD 8.2) vs 24.4 [(SD 9.1), P < .00]. Overall, OOP drugs were linked to higher symptom burden (P < .001) and financial toxicity (P < .001).
Conclusions: The severity of symptoms and their management with OOP medications was significantly associated with patients' financial toxicity. These findings highlight the importance of integrating financial toxicity assessment into routine cancer care to optimize patient outcomes and well-being.
期刊介绍：
The Oncologist® is dedicated to translating the latest research developments into the best multidimensional care for cancer patients. Thus, The Oncologist is committed to helping physicians excel in this ever-expanding environment through the publication of timely reviews, original studies, and commentaries on important developments. We believe that the practice of oncology requires both an understanding of a range of disciplines encompassing basic science related to cancer, translational research, and clinical practice, but also the socioeconomic and psychosocial factors that determine access to care and quality of life and function following cancer treatment.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
